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Introduction: With the rise in antibiotic resistance, tigecycline has been used frequently
in off-label indications, based on its in-vitro activity against multidrug-resistant organisms.
In this study, our aim was to assess its use in approved and unapproved indications.
Materials and Methods: This is a retrospective chart review evaluating a 2-year
experience of tigecycline use for > 72 h in 153 adult patients inside and outside critical
care unit from January 2012 to December 2013 in a Lebanese tertiary-care hospital.
Results: Tigecycline wasmostly used in off-label indications (81%) and prescribed inside
the critical care area, where the number of tigecycline cycles was 16/1,000 patient days.
Clinical success was achieved in 43.4% of the patients. In the critically ill group, it was
significantly higher in patients with a SOFA score <7 using multivariate analysis (Odds
Ratio (OR) = 12.51 [4.29–36.51], P < 0.0001). Microbiological success was achieved
in 43.3% of patients. Yet, the univariate and adjusted multivariate models failed to show
a significant difference in this outcome between patients inside vs. outside critical care
area, those with SOFA score <7 vs. ≥ 7, and in FDA-approved vs. off-label indications.
Total mortality reached ∼45%. It was significantly higher in critically ill patients with SOFA
score ≥7 (OR = 5.17 [2.43–11.01], P < 0.0001) and in off-label indications (OR = 4.00
[1.30–12.31], P = 0.01) using an adjusted multivariate model. Gram-negative bacteria
represented the majority of the clinical isolates (81%) and Acinetobacter baumannii
predominated (28%). Carbapenem resistance was present in 85% of the recovered
Acinetobacter, yet, more than two third of the carbapenem-resistant Acinetobacter
species were still susceptible to tigecycline.
Conclusion: In our series, tigecycline has been mostly used in off-label indications,
specifically in severely ill patients. The outcome of such infections was not inferior to that
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of FDA-approved indications, especially inside critical care area. The use of this
last resort antibiotic in complicated clinical scenarios with baseline microbiological
epidemiology predominated by extensively-drug resistant pathogens ought to be
organized.
Keywords: tigecycline, critically ill, off-label indications, Acinetobacter baumannii, antibiotic resistance, antibiotic
stewardship
INTRODUCTION
The emergence of antimicrobial resistance among gram-
positive and gram-negative organisms has led to the famous
“bad bugs, no drugs” situation encountered primarily with
the “ESKAPE” pathogens (Boucher et al., 2009). The
paucity of active agents against organisms such as extensive
drug-resistant (XDR) Acinetobacter baumannii (XDR-
AB), carbapenem-resistant Enterobacteriaceae (CRE), and
carbapenem-resistant Pseudomonas aeruginosa has led to
the use of old antibiotics that were previously abandoned
because of their toxicity, such as polymyxins, or the
premature use of new antimicrobials in indications where
they have not yet been proved to be active (Bassetti and Righi,
2015).
Tigecycline, the first in-class glycylcycline, was first approved
by the Food and Drug Administration (FDA) and then by the
European Medicines Agency in 2005 and 2006, respectively, for
the treatment of complicated intra-abdominal infections (cIAIs;
Babinchak et al., 2005) and complicated skin and soft-tissue
infections (cSSTIs) in adults (Ellis-Grosse et al., 2005). In 2009,
the FDA added community-acquired bacterial pneumonia (CAP)
in adults to the list of approved indications (Tanaseanu et al.,
2008). Tigecycline has demonstrated a promising in vitro activity
against extended spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae, CRE, and XDR-AB (Mendes et al., 2010;
Balode et al., 2013; Sader et al., 2015). Because of the absence
of other treatment options, it has been administered off-label
for treating infections including hospital-acquired pneumonia
(HAP), ventilator-associated pneumonia (VAP), urinary tract
infections (UTI), sepsis, bacteremia, and febrile neutropenia (De
Rosa et al., 2015).
Tigecycline has been widely used in our healthcare institution
for the management of hospital-acquired infections caused
by multidrug-resistant bacteria, without a specified protocol.
Whether it should be used as a last-resort treatment option
for such indications remains a complex issue that necessitates
ongoing assessment. We retrospectively reviewed the prescribing
pattern of tigecycline in a real-life clinical situation. We
correlated its use to the microbiological ecology in this healthcare
setting with regard to the prevalent XDR gram-negative
resistance.
MATERIALS AND METHODS
Study Design and Patients
This is a retrospective chart review conducted at Makassed
General Hospital, a 200-bed university hospital located in
Beirut, Lebanon, with a 13-bed critical care unit, between
January 2012 and December 2013. It included 153 adult
patients who received tigecycline for more than 72 h.
The hospital’s Institutional Review Board committee
approved this study. All patients received the standard
FDA-approved dosage of tigecycline: a loading dose of
100 mg, followed by 50mg administered intravenously
every 12 h.
We recorded baseline clinical and demographic
characteristics, microbiological findings, indication for
tigecycline therapy, concomitant use of other antibiotics, clinical
and microbiological outcome, and mortality. FDA-approved
indications were CAP, cSSTI, and cIAI. Off-label indications were
HAP, VAP, UTI, diabetic ulcers, sepsis, bacteremia, and febrile
neutropenia. Severity of underlying disease was assessed with
sequential organ failure assessment (SOFA) score for critically ill
patients.
Definitions
Infections were defined according to clinical diagnostic criteria
established by the Center of Disease Control and Prevention
and other international guidelines (Garner et al., 1988; Centers
for Disease Control Prevention, 2012; Dellinger et al., 2013).
Infections were classified as nosocomial acquired when onset
occurred more than 48 h after hospital admission, and the
infection was not present or incubating at that time (Garner
et al., 1988). Infections occurring within 48 h of admission to the
hospital were considered community-acquired, unless the patient
had been transferred directly from another healthcare facility
or discharged within the 30 days preceding hospital admission
(Garner et al., 1988).
Empiric use of tigecycline was defined as its administration
to a patient with signs and symptoms of infection without an
identified source or a specific microbiological isolate (Bassetti
et al., 2010). Targeted therapy was defined as tigecycline
administration in the presence of an identified isolate (Bassetti
et al., 2010).
As recommended by the World health Organization (WHO),
tigecycline consumption was reported in Defined Daily Doses
(DDD)/100 Bed Days (BD), a standardized figure that provides
a degree of comparison among in-patients in different hospitals
(World Health Organization, 2003). DDD corresponds to the
assumed average daily dose of a specific drug for its main
indication in adults (World Health Organization, 2003). Number
of BD = Number of beds × occupancy index × Number of days
(during that period). A bed-day corresponds to one occupied
hospital bed during 1 day (World Health Organization, 2003).
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Microbiological Studies and Breakpoints of
Resistance
Bacterial identification was performed according to standard
microbiological procedures. Antibiotic susceptibility was
performed using the disc diffusion method as recommended
by the Clinical and Laboratory Standards Institute (CLSI) for
all organisms (CLSI, 2016). Quality-control strains used in
the testing of Acinetobacter species and P. aeruginosa, and
the Enterobacteriaceae were E. coli American Type Culture
Collection (ATCC) 25922 and P. aeruginosa ATCC 27853.
Acinetobacter species susceptibility was tested against all
antimicrobials enlisted in CLSI guidelines (CLSI, 2016) except
for ampicillin-sulbactam since it is non-available in Lebanon.
Extensive drug resistance in A. baumannii was defined as
non-susceptibility to at least one agent in all but susceptible
to only one or two categories (Magiorakos et al., 2012).
In our center, isolates were considered XDR if they were
susceptible to tigecycline and colistin only and resistant to
the following categories: aminoglycosides, antipseudomonal
carbapenems, antipseudomonal FQs, extended-spectrum
cephalosporins, antipseudomonal penicillins plus beta-lactamase
inhibitors, monobactams and trimethoprim/sulfamethoxazole
(TMP/SMX).
A 15-µg disc of tigecycline (Oxoid Ltd, Cambridge, UK)
was used to determine susceptibility, and the breakpoints
suggested by the FDA for Enterobacteriaceae (susceptible ≥19
mm; intermediate 15–18 mm, and resistant ≤14 mm), and
gram-positive microorganisms (susceptible ≥19 mm) were used
(Tygacil package insert, June 2005, Wyeth Pharmaceuticals,
Inc., Philadelphia, PA). Tigecycline clinical breakpoints using
the disc-diffusion method against A. baumanii have not been
established by the CLSI (2016) or by the European Committee on
Antimicrobial Susceptibility Testing (The European Committee
on Antimicrobial Susceptibility Testing, 2016). Therefore, we
applied the clinical breakpoints suggested by Jones et al.
(2007) (susceptible ≥16 mm, intermediate 13–15 mm, and
resistant ≤12 mm). Our medical laboratory department does
not routinely perform broth microdilution method and a
reference laboratory is not available in our country. However,
during the study period, 11 randomly selected strains of
A. baumanii were sent to another clinical microbiology
laboratory (Faculty of Medicine andMedical Sciences, University
of Balamand, Amioun, Lebanon) at a rate of one strain
per 45 days when available, where broth microdilution
method was performed for evaluating colistin and tigecycline
susceptibility. We found 100% correlation between results
of disc diffusion and broth microdilution (Supplementary
File 1).
Clinical Outcome
Clinical success was defined as a positive response (partial or
complete improvement of signs/symptoms of infection) and the
lack of need to use a new antibiotic for the initial infection
for 72 h after the discontinuation of tigecycline (Kuo et al.,
2011; Montravers et al., 2014). Persistence or deterioration
of the initial infection symptoms/signs requiring a change of
antibiotic therapy, an infection-related death occurring later than
48 h after the start of tigecycline, and/or premature treatment
discontinuation because of a tigecycline-related adverse event
were considered clinical failures (Montravers et al., 2014; Kuo
et al., 2011). Cases of insufficient data, death not directly related
to the initial infection or occurring within the first 48 h of
treatment, or the addition of an antibacterial agent for another
infection (Montravers et al., 2014) were considered to be an
undetermined clinical response.
Microbiological Outcome
Microbiological success was defined as the eradication/sterile
culture results during or after the course of antibiotic therapy
(Montravers et al., 2014). The persistent identification of the same
organism for 72 h after initiation of antibiotic treatment was
considered a microbiological failure (Montravers et al., 2014).
Superinfection was defined as a new isolate obtained during
the treatment of the original infection with development of
symptoms and signs of clinical infection (Kuo et al., 2011). A
specimen that was not available for estimation of eradication
was considered an unavailable response (Montravers et al.,
2014). Because our study was retrospective, microbiological
success rates were calculated when follow-up cultures were
available.
Mortality
Seven days post-treatment mortality, a surrogate marker for
treatment failure, was defined as death occurring within 48 h
up to 7 days after the end of tigecycline therapy. In-hospital
mortality, a surrogate marker of the general patient condition,
was defined as the death occurring between 7 and 30 days
after finishing tigecycline therapy. Total mortality was the
sum of both 7 days post-treatment mortality and in-hospital
mortality.
Statistical Analysis
The Statistical Package for Social Sciences program (IBM SPSS
Statistics for Windows, Version 23.0, IBM Corp., Armonk, NY,
USA) was used for data entry, management, and analyses.
Descriptive analysis was carried out for categorical variables by
number and percent. We assessed through univariate analysis
the significance of baseline characteristics, comorbidities, types of
infections, treatment strategy, outcome and mortality in patients
who received tigecycline inside vs. outside critical care, and
those with SOFA score <7 vs. those with SOFA score ≥7 inside
ICU. Univariate analysis for the groups was carried out using
the Chi square test for categorical variables, and independent
t-test for continuous ones. This was followed by multivariate
logistic regression for outcome and mortality to assess further
significance between the groups, while controlling for potentially
confounding variables. Parameters with P< 0.05 at the univariate
level and other clinically significant variables were included in
the multivariate model. Results were presented as odds ratio
(OR) and 95% confidence interval (CI). We also performed
univariate and multivariate analyses for outcome and mortality
in FDA-approved indications vs. off-label indications.
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RESULTS
Patients’ Clinical Characteristics
In total, 153 patients received tigecycline therapy within our
healthcare facility between January 2012 and December 2013.
The clinical characteristics of the patients are reported in
Table 1. Most of them were elderly, with an age above 65 years
(53%). This population suffered from multiple comorbidities,
including cardiovascular disease (59%), diabetes (30%), acute
renal failure (23%), and hemodynamic insufficiency (14%). One
third of our patients (30.7%) were critically ill, thus justifying
the use of intravenous catecholamines (24%) and mechanical
ventilation (23%).
Critically ill patients had a significantly higher incidence of
cardiovascular disease (77%, P = 0.003) compared to those
outside critical care area. Also, the need for vasopressors and
mechanical ventilation was equally higher in this category (38%,
P = 0.01 and 36%, P = 0.01, respectively) compared with
the other group. In the critically ill group, the incidence of
cardiovascular disease, acute renal injury, as well as the need
for vasopressors was significantly higher in the sicker category
of these patients, i.e., those with SOFA ≥7 (87%, P =0.03; 37%,
P= 0.02 and 53%, P= 0.05, respectively) in comparison to those
with a SOFA score <7.
Tigecycline Consumption and Duration of
Therapy
During 2012 and 2013, respectively, tigecycline consumption
reached 2.6 DDD/100BD and 4 DDD/100 BD in our facility. The
majority of the patients received tigecycline for a duration of
between 72 h and 10 days (64%), with amedian duration of 8 days
(Table 2). According to each indication, the median duration of
therapy varied between 6.5 and 9.5 days. The range varied from 3
to 30 days. The longest duration of tigecycline therapy was seen in
cases with febrile neutropenia (median 7 days; range 3–30 days;
Table 2).
Site of Care
During the study period, the number of patient days was
89,800 in the hospital and 2777 in the critical care unit.
Tigecycline was prescribed much more outside the critical care
unit than inside it (106 patients vs. 47 patients, respectively;
Table 1). However, on adjusting these values to patient days, the
number of tigecycline cycles was 16/1,000 patient days inside
the critical care unit and 1.2/1,000 patient days outside it.
Inside the critical care area, tigecycline was mostly prescribed
to patients with a SOFA score ≥7 (30/47 patients, 64% of the
critically ill category). These patients have been at a higher
risk of contracting multidrug-resistant A. baumannii infection
compared with patients. According to our infection control data,
it has been endemic in the critical care area of our facility.
Indication for Tigecycline
Tigecycline was prescribed more in off-label indications (124/153
patients, 81%) than in FDA-approved indications (29/153
patients, 19%; Table 1).
FDA-Approved Indications
Overall, cSSTIs were the most common (18/29, 62.1%) infections
in this category followed by CAP (8/29, 27.6%). Inside the critical
care area, CAP was the most common FDA-approved indication
(4/6 patients, 66.7%) and all patients who were treated with
tigecycline for an FDA-approved indication had a SOFA score
<7 (6/17, 35.3%). Outside the critical care area, tigecycline was
prescribed mostly in cSSTIs (23/29, 79.3%) compared with cIAI
(4/29, 13.8%) and CAP (4/29, 13.8%).
Off-Label Indications
In general, VAP was the most common indication (39/124
patients, 31.5%), followed by HAP (30/124, 24.2%). Irrespective
of the SOFA score, half of the critically ill patients treated with
tigecycline had VAP (24/47 patients, 51.1%). Outside critical care,
off-label indications were also a majority (83/106 patients, 78%).
Fever with neutropenia represented the leading indication (23/83
patients, 27.7%; Table 1).
Strategy of Treatment
Tigecycline was used as targeted therapy in 56% of the cases
(86/153 patients) and as empiric therapy in 44% (67/153 patients;
Table 1). Empiric use was significantly higher outside critical care
(49%, P= 0.049), unlike targeted therapy, which was significantly
higher inside critical care area (68%, P = 0.049).
Tigecycline was combined with other antibiotics in 89%
(136/153) of the cases without statistically significant difference
between groups. Overall, tigecycline was most frequently
combined with carbapenems (51/153, 46%) followed by colistin
(47/153 patients, 30.7%) and piperacillin/tazobactam (38/153
patients, 24.8%).
Clinical Outcome
Because of the retrospective nature of the study, clinical success
rates were calculated in patients with a known clinical outcome.
Clinical success was achieved in 43.4% of the whole patient
population (59/136 patients; Table 3). It was significantly higher
in patients treated outside critical care compared to those inside
ICU at the univariate level (49.5 vs. 31%, P = 0.04). Yet, the
adjusted multivariate model failed to confirm this finding, where
there was an insignificant difference between the two groups
upon controlling for the following potentially confounding
variables (OR= 1.07 [0.45–2.57], P = 0.87; Table 3).
In the critically ill category, clinical success was significantly
higher in patients with a SOFA score <7 compared with those
with a SOFA score ≥7 using both univariate (62.5 vs. 13.8%, P =
0.003) and multivariate (OR = 12.51 [4.29–36.51], P < 0.0001)
models (Table 4).
With respect to the indication, clinical success was
significantly higher in the FDA-approved group compared
with the off-label group through univariate analysis (64 vs.
38.7%, P = 0.02). However, this finding was not confirmed by
multivariate analysis (Table 5).
CAP showed the highest success rate within the FDA-
approved category (85.7%), whereas febrile neutropenia showed
the best clinical outcome in the off-label category (84.2%). Septic
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TABLE 1 | Univariate analysis for baseline characteristics, comorbidities, types of infections, and treatment strategy in patients who received tigecycline
inside and outside critical care, and those with SOFA score <7 and ≥7 inside critical care during the study period (N = 153 patients).
Clinical characteristics and treatment
strategy
Total (N = 153) Critically ill Non-critically ill P Critically ill with SOFA Critically ill with SOFA P
(n = 47) (n = 106) < 7 (n = 17) ≥7 (n = 30)
AGE (YEARS)
<45 35 (22.9%) 12 (25.5%) 23 (21.7%) 0.09 7 (41.2%) 5 (16.7%) 0.02
>45 and ≤65 37 (24.2%) 6 (12.8%) 31 (29.2%) 4 (23.5%) 2 (6.7%)
>65 81 (52.9%) 29 (61.7%) 52 (49.1%) 6 (35.3%) 23 (76.7%)
GENDER
Male 79 (51.6%) 23 (48.9%) 56 (52.8%) 0.66 6 (35.3%) 17 (56.7%) 0.16
Female 74 (48.4%) 24 (51.1%) 50 (47.2%) 11 (64.7%) 13 (43.3%)
COMORBIDITIES AND RISK FACTORS
Cardiovascular Disease 90 (58.8%) 36 (76.6%) 54 (50.9%) 0.003 10 (58.8%) 26 (86.7%) 0.03
Diabetes 46 (30.1%) 19 (40.4%) 27 (25.5%) 0.06 5 (29.4%) 14 (46.7%) 0.25
COPD 21 (13.7%) 10 (21.3%) 11 (10.4%) 0.07 4 (23.5%) 6 (20.0%) 0.78
ARF 35 (22.9%) 12 (25.5%) 23 (21.7%) 0.60 1 (5.9%) 11 (36.7%) 0.02
CKD 19 (12.4%) 7 (14.9%) 12 (11.3%) 0.54 1 (5.9%) 6 (20.0%) 0.19
CHD 6 (3.9%) 0 (0.0%) 6 (5.7%) 0.10 0 (0.0%) 0 (0.0%) NA
Hemodynamic Failure 22 (14.4%) 7 (14.9%) 15 (14.2%) 0.90 1 (5.9%) 6 (20.0%) 0.19
Vasopressors given before or ≤24 h of
tigecycline therapy
37 (24.2%) 18 (38.3%) 19 (17.9%) 0.01 2 (11.8%) 16 (53.3%) 0.005
Mechanical ventilation 35 (22.9%) 17 (36.2%) 18 (17.0%) 0.01 4 (23.5%) 13 (43.3%) 0.17
Neutropenia (<500 mm3 ) 30 (19.6%) 2 (4.3%) 28 (26.4%) 0.001 0 (0.0%) 2 (6.7%) 0.28
MALIGNANCY
No cancer 103 (67.3%) 45 (95.7%) 58 (54.7%) <0.0001 17 (100.0%) 28 (93.3%) 0.55
Leukemia 24 (15.7%) 1 (2.1%) 23 (21.7%) 0 (0.0%) 1 (3.3%)
Lymphoma 11 (7.2%) 0 (0.0%) 11 (10.4%) 0 (0.0%) 0 (0.0%)
Solid Tumor 15 (9.8%) 1 (2.1%) 14 (13.2%) 0 (0.0%) 1 (3.3%)
HSCT
No 139 (90.8%) 47 (100.0%) 92 (86.8%) 17 (100.0%) 30 (100.0%) NA
Autologous 4 (2.6%) 0 (0.0%) 4 (3.8%) 0.03 0 (0.0%) 0 (0.0%)
Allogeneic 10 (6.5%) 0 (0.0%) 10 (9.4%) 0 (0.0%) 0 (0.0%)
DURATION OF TIGECYCLINE THERAPY
72 h–10 days 98 (64.1%) 31 (66.0%) 67 (63.2%) 0.76 11 (64.7%) 20 (66.7%) 0.92
≥11–14 days 28 (18.3%) 7 (14.9%) 21 (19.8%) 3 (17.6%) 4 (13.3%)
≥15 days 27 (17.6%) 9 (19.1%) 18 (17.0%) 3 (17.6%) 6 (20%)
INDICATIONS FOR TIGECYCLINE THERAPY
FDA approved Indications 29 (19.0%) 6 (12.8%) 23 (21.7%) 0.19 6 (35.3%) 0 (0.0%) <0.0001
cSSTI 18 (11.8%) 2 (4.3%) 16 (15.1%) 0.055 2 (11.8%) 0 (0.0%) 0.055
cIAI 4 (2.6%) 0 (0.0%) 4 (3.8%) 0.18 0 (0.0%) 0 (0.0%) NA
CAP 8 (5.2%) 4 (8.5%) 4 (3.8%) 0.22 4 (23.5%) 0 (0.0%) 0.005
Off-label Indications 124 (81.0%) 41 (87.2%) 83 (78.3%) 0.19 11 (64.7%) 30 (100.0%) <0.0001
HAP 30 (19.6%) 11 (23.4%) 19 (17.9%) 0.43 2 (11.8%) 9 (30.0%) 0.16
VAP 39 (25.5%) 24 (51.1%) 15 (14.2%) <0.0001 8 (47.1%) 16 (53.3%) 0.68
Bacteremia 16 (10.5%) 7 (14.9%) 9 (8.5%) 0.23 3 (17.6%) 4 (13.3%) 0.69
Sepsis 14 (9.2%) 2 (4.3%) 12 (11.3%) 0.16 0 (0.0%) 2 (6.7%) 0.28
Diabetic Ulcer 8 (5.2%) 2 (4.3%) 6 (5.7%) 0.72 1 (5.9%) 1 (3.3%) 0.68
UTI 6 (3.9%) 1 (2.1%) 5 (4.7%) 0.45 0 (0.0%) 1 (3.3%) 0.45
FN 24 (15.7%) 1 (2.1%) 23 (21.7%) 0.002 0 (0.0%) 1 (3.3%) 0.45
TREATMENT STRATEGY
Empiric 67 (43.8%) 15 (31.9%) 52 (49.1%) 0.049 5 (29.4%) 10 (33.3%) 0.78
Targeted 86 (56.2%) 32 (68.1%) 54 (50.9%) 12 (70.6%) 20 (66.7%)
(Continued)
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TABLE 1 | Continued
Clinical characteristics and treatment
strategy
Total (N = 153) Critically ill Non-critically ill P Critically ill with SOFA Critically ill with SOFA P
(n = 47) (n = 106) < 7 (n = 17) ≥7 (n = 30)
Monotherapy 17 (11.1%) 4 (8.5%) 13 (12.3%) 0.50 1 (5.9%) 3 (10.0%) 0.63
Combination therapy 136 (88.9%) 43 (91.5%) 93 (87.7%) 16 (94.1%) 27 (90.0%)
TGC+3GC 3 (2.0%) 0 (0.0%) 3 (2.8%) 0.24 0 (0.0%) 0 (0.0%) NA
TGC+4GC 23 (15.0%) 5 (10.6%) 18 (17.0%) 0.31 3 (17.6%) 2 (6.7%) 0.24
TGC+TZP 38 (24.8%) 16 (34.0%) 22 (20.8%) 0.08 7 (41.2%) 9 (30.0%) 0.44
TGC+CAR 71 (46.4%) 27 (57.4%) 44 (41.5%) 0.07 8 (47.1%) 19 (63.3%) 0.28
TGC+CST 47 (30.7%) 16 (34.0%) 31 (29.2%) 0.55 6 (35.3%) 10 (33.3%) 0.89
TGC+AMG 29 (19.0%) 3 (6.4%) 26 (24.5%) 0.01 3 (17.6%) 0 (0.0%) 0.02
TGC+TZP+CST 12 (7.8%) 4 (8.5%) 8 (7.5%) 0.84 1 (5.9%) 3 (10.0%) 0.63
TGC+CAR+CST 26 (17.0%) 10 (21.3%) 16 (15.1%) 0.35 4 (23.5%) 6 (20.0%) 0.78
TGC+AMG+CST 11 (7.2%) 3 (6.4%) 8 (7.5%) 0.80 3 (17.6%) 0 (0.0%) 0.02
TGC+CAR+AMG 10 (6.5%) 1 (2.1%) 9 (8.5%) 0.14 1 (5.9%) 0 (0.0%) 0.18
TGC+TZP+AMG 7 (4.6%) 0 (0.0%) 7 (6.6%) 0.07 0 (0.0%) 0 (0.0%) NA
TGC+VAN 23 (15.0%) 5 (10.6%) 18 (17.0%) 0.31 2 (11.8%) 3 (10.0%) 0.85
TGC+TEC 27 (17.6%) 5 (10.6%) 22 (20.8%) 0.13 3 (17.6%) 2 (6.7%) 0.24
AMG, Aminoglycoside; ARI, Acute Renal Injury; CAP, Community Acquired Pneumonia; CAR, Carbapenem; CHD, Chronic Hepatic disease; cIAI, complicated Intra-abdominal Infection;
CKD, Chronic Kidney Disease; COPD, Chronic Obstructive Pulmonary Disease; cSSTI, complicated Skin and Soft Tissue Infection; CST, Colistin; d, days; FDA, Food and Drug
Administration; FN, Febrile Neutropenia; HAP, Hospital Acquired Pneumonia; HSCT, Hematopoietic Stem Cell Transplantation; NA, Not Applicable; SOFA, Sequential Organ Failure
Assessment; TEC, Teicoplanin; TGC, Tigecycline; TZP, Piperacillin/Tazobactam; UTI, Urinary Tract Infection; VAN, Vancomycin; VAP, Ventilator Associated Pneumonia; 3GC, Third
Generation Cephalosporin; 4GC, Fourth Generation Cephalosporin.
N.B. Calculation of clinical and microbiological success and failure rates for all categories is done as such:
1-Clinical success rate (%) = Number of patients with clinical success/(Number of patients with clinical success + Number of patients with clinical failure) × 100.
2-Microbiological success rate (%) = Number of patients with microbiological success / (Number of patients with microbiological success + Number of patients with microbiological
failure) × 100.
patients receiving tigecycline showed the lowest clinical success
rate (1/14 patients, 7.1%; Table 2).
Microbiological Outcome
Microbiological success rate was determined in cases in
which follow-up cultures were available from patients’ charts.
Microbiological eradication of infection was achieved in 43.3%
of patients who received tigecycline therapy (Table 3).
Yet, the univariate and multivariate models failed to show a
significant difference in this outcome between patients inside vs.
outside critical care area, those with SOFA score <7 vs. ≥7, and
in FDA-approved vs. off-label indications (Tables 3, 4, 5).
Mortality
Total mortality rate reached 45% in this study including 33%
7 day post-treatment mortality and 12% in hospital mortality.
Findings of univariate and multivariate analysis show that there
was not any statistically significant difference in these three types
of mortality between patients inside and outside critical care
(Table 3).
However, upon comparing patients with SOFA score ≥7 and
those with SOFA score <7, only total mortality and 7 day post-
treatment mortality were significantly higher in patients in the
former group at the univariate (P < 0.0001) and multivariate
levels (OR = 5.17 [2.43–11.01], P < 0.0001; OR = 6.41 [3.04–
13.52], P < 0.0001, respectively; Table 4).
With respect to the indication, total mortality, and 7 days post-
treatment mortality rates were significantly higher in the off-label
indication group compared to the FDA-approved group, using
univariate analysis (51.6 vs. 17.2%, P = 0.001; 38.7 vs. 10.3%,
P = 0.004, respectively). However, the adjusted multivariate
model confirmed this result for total mortality only (OR= 4.00
[1.30–12.31], P = 0.01; Table 5).
Microbiological Findings and Isolate
Susceptibility to Tigecycline
Distribution of gram-positive and gram-negative bacteria
isolated from clinical specimens during the study period is shown
in Figure 1. Gram-negative bacteria represented the majority of
the clinical isolates (304/374 isolates, 81%; Supplementary File 2).
Susceptibility to tigecycline reached 89% (194/217 isolates) in
the gram-negative species and 91% (20/22 isolates) in the gram-
positive species, as determined by the disc-diffusion method.
A. baumannii (105/374 isolates, 28%) was predominant among
the gram-negative species, of which 85% (87/102 isolates) were
resistant to carbapenems. Yet, 82% (71/87 isolates) of the
carbapenem-resistant Acinetobacter species were susceptible to
tigecycline (XDR-AB). Pseudomonas species susceptibility to
tigecycline was not tested (Table 4).
E. coli and Klebsiella species represented 16% (60/374 isolates)
and 13% (48/374 isolates) of the total isolates, respectively. No
carbapenem resistance was detected in either species. Overall,
98% (54/55 isolates) of the E. coli isolates were susceptible to
tigecycline. Further, 77% of the E. coli isolates (46/60 isolates)
were third-generation cephalosporin (3GC) resistant, of which
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TABLE 3 | Univariate and multivariate analysis for clinical outcome, microbiological outcome and mortality in patients treated with tigecycline inside vs.
outside the critical care area.
Variables Total (N= 153) Univariate model Adjusted multivariate model*
Critically ill patients Patients outside critical P Odds ratio P
(n = 47) care area (n = 106) (95 % confidence interval)
Clinical
Outcome
Success 59 (43.4%)
77 (56.6%)
14 (31.1%)
31 (68.9%)
45 (49.5%)
46 (50.5%)
0.04 1.07 (0.45–2.57) 0.87
Failure
Microbiological
Outcome
Success 26 (43.3%)
34 (56.7%)
8 (36.4%)
14 (63.6%)
18 (47.4%)
20 (52.6%)
0.41 0.96 (0.29–3.26) 0.95
Failure
Total mortality 69 (45.1%) 25 (53.2%) 44 (41.5%) 0.18 0.82 (0.36–1.89) 0.65
7 days
post-treatment
mortality
51 (33.3%) 20 (42.6%) 31 (29.2%) 0.11 1.15 (0.52–2.54) 0.73
In-hospital
mortality
18 (11.8%) 5 (10.6%) 13 (12.3%) 0.77 0.85 (0.28–2.54) 0.77
Potentially confounding variables controlled for in the adjusted model *were: cardiovascular disease, vasopressors given before or ≤24 h of tigecycline therapy, mechanical ventilation,
neutropenia (<500 mm3 ), ventilator associated pneumonia, treatment strategy; combination therapy using tigecycline plus aminoglycoside.
N.B. Calculation of clinical and microbiological success and failure rates for all categories is done as such:
1-Clinical success rate (%) = Number of patients with clinical success/(Number of patients with clinical success + Number of patients with clinical failure) × 100.
2-Microbiological success rate (%) = Number of patients with microbiological success/(Number of patients with microbiological success + Number of patients with microbiological
failure) × 100.
TABLE 4 | Univariate and multivariate analysis for clinical outcome, microbiological outcome and mortality in patients with SOFA score <7 and ≥7
receiving tigecycline therapy inside the critical care area.
Variables Critically ill patients (n = 47) Univariate model Adjusted multivariate model*
SOFA score < 7 SOFA ≥7 P Odds ratio P
(n = 17) (n = 30) (95 % confidence interval)
Clinical
Outcome
Success 14 (31.1%)
31 (68.9%)
10 (62.5%)
6 (37.5%)
4 (13.8%)
25 (86.2%)
0.001 12.51 (4.29–36.51) <0.0001
Failure
Microbiological
Outcome
Success 8 (36.4%)
14 (63.6%)
3 (33.3%)
6 (66.7%)
5 (38.5%)
8 (61.5%)
0.81 1.29 (0.37–4.54) 0.69
Failure
Total mortality 25 (53.2%) 2 (11.8%) 23 (76.7%) <0.0001 5.17 (2.43–11.01) <0.0001
7 days
post-treatment
mortality
20 (42.6%) 0 (0.0%) 20 (66.7%) <0.0001 6.41 (3.04–13.52) <0.0001
In-hospital
mortality
5 (10.6%) 2 (11.8%) 3 (10.0%) 0.85 1.32 (0.63–2.77) 0.46
Potentially confounding variables controlled for in the adjustedmodel*were: age, cardiovascular disease, FDA-approved indications, off-label indications, community acquired pneumonia,
and combination therapy using tigecycline plus aminoglycoside plus colistin.
N.B. Calculation of clinical and microbiological success and failure rates for all categories is done as such:
1-Clinical success rate (%) = Number of patients with clinical success/(Number of patients with clinical success + Number of patients with clinical failure) × 100.
2-Microbiological success rate (%) = Number of patients with microbiological success/(Number of patients with microbiological success + Number of patients with microbiological
failure) × 100.
98% (43/44 isolates) were susceptible to tigecycline. With respect
to Klebsiella species, 87% (40/46 isolates) were susceptible to
tigecycline. Approximately 39% (18/48 isolates) were resistant to
3GCs, of which 78% (14/18 isolates) were tigecycline sensitive.
P. aeruginosa was present in 12% (45/374 isolates) of the
cultured bacteria, where 9% (4/45 isolates) were ceftazidime
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TABLE 5 | Univariate and multivariate analysis for clinical outcome, microbiological outcome, and mortality in FDA-approved vs. off-label indications.
Variables Univariate model Adjusted multivariate model*
FDA-approved
indications
Off-label
indications
P Odds ratio P
(n = 29) (n = 124) (95 % confidence interval)
Clinical
Outcome
Success 16 (64%)
9 (36%)
43 (38.7%)
68 (61.3%)
0.02 1.65 (0.60–4.49) 0.33
Failure
Microbiological
Outcome
Success
Failure
6 (50%)
6 (50%)
20 (16.1%)
104 (83.9%)
0.58 1.07 (0.38–2.97) 0.90
Total mortality 5 (17.2%) 64 (51.6%) 0.001 4.00 (1.30–12.31) 0.01
7 days
post-treatment
mortality
3 (10.3%) 48 (38.7%) 0.004 3.50 (0.97–12.61) 0.05
In-hospital
mortality
2 (6.9%) 16 (12.9%) 0.53 2.00 (0.43–9.23) 0.37
Potentially confounding variables controlled for in the adjusted model *were: cardiovascular disease, vasopressors given before or ≤24 h of tigecycline therapy, hemodynamic failure,
mechanical ventilation, treatment strategy, monotherapy, and combination therapy.
FIGURE 1 | Distribution of gram-positive and gram-negative bacteria isolated from clinical specimens during the study period. MRSA, methicillin
resistant Staphylococcus aureus; MSSA, methicillin sensitive Staphylococcus aureus; CR, carbapenem resistant; CS, carbapenem sensitive; 3GCR, third generation
cephalosporin.
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resistant and 44% (20/45 isolates) were carbapenem resistant
(Table 4).
Among gram-positive bacteria, Enterococci represented 5%
(19/374) of the total isolates, where none was vancomycin
resistant. Tigecycline susceptibility was 83% (10/12) in this
group. Staphylococcus aureus represented 3% (11/374) of the total
isolates, where 55% (6/11) were methicillin resistant. All S. aureus
strains were susceptible to tigecycline.
DISCUSSION
This study describes a single-center experience of tigecycline use
in hospitalized patients in the absence of specific institutional
guidelines for antibiotic use. It has been used in both FDA-
approved indications such as cSSTI, cIAI, and CAP, and in off-
label indications such as nosocomial pneumonia, bacteremia,
febrile neutropenia, and UTI. Clinical and microbiological
success rates were higher for the approved indications compared
with the non-approved ones: 64 and 50% vs. 39 and 42%,
respectively. In addition, total mortality was found to be
significantly higher in the off-label indications compared with
FDA-approved indications (OR= 4.00 [1.30–12.31], P = 0.01).
Upon comparing our results to pivotal studies from the
literature, we found higher success rates in patients treated
with tigecycline for FDA-approved indications as reported by
Babinchack et al. for cIAI (80%; Babinchak et al., 2005), Ellis-
Grosse et al. for cSSTI (80%; Ellis-Grosse et al., 2005), and
Tanaseanu et al. for CAP (81%; Tanaseanu et al., 2008). This
difference in patient outcome could be due to two factors.
First, one half of our patients were critically ill and two
thirds of them had a SOFA score >7. Second, the recovered
bacterial species in our study were mostly MDR and XDR
gram-negative species. Comparatively, in the aforementioned
studies, the organisms were mostly gram-positive species
in cSSTIs and antibiotic-susceptible gram-negative species
in cIAIs.
In the study by Babinchak et al. (2005), the mortality rate
in the tigecycline arm was higher than that of the comparator
arm, imipenem-cilastatin. This study stated that the majority of
patients who died had serious underlying preexisting conditions,
tended to be over 65 years of age, and had relatively high
severity-of-illness scores (Babinchak et al., 2005). Subsequently,
in September 2010, the FDA issued a black box warning for an
increased risk of death with the use of tigecycline, based on a
pooled analysis of 13 phase III and phase IV clinical trials for
both approved and unapproved indications (US FDA, 2010). In
a recent study reviewing the in vitro susceptibility of tigecycline
and comparators against gram-positive and gram-negative
isolates collected from the Middle East and Africa between
2004 and 2011, the authors found that minimal inhibitory
concentration (MIC 90) of ESBL-producing E. coli and Klebsiella
species is higher than that in non-ESBL-producing species (Kanj
et al., 2014). Given the fact that tigecycline highly concentrates
in the biliary tree and moderately in the colon (De Rosa et al.,
2015), we recommend its use only in non-critically ill patients
for intrabiliary infections using the standard FDA-approved dose
and for extrabiliary intra-abdominal infections using a double
dose (200mg loading dose followed by a maintenance dose of
100mg every 12 h), especially if ESBL-producing organisms are
expected or documented.
As for cSSTIs, tigecycline showed non-inferiority to
vancomycin-aztreonam combination in two phase III, double-
blind studies in hospitalized adults (Ellis-Grosse et al., 2005). In
these trials, gram-positive species were predominant, including
13%methicillin-resistant S. aureus and 8% vancomycin-sensitive
Enterococci. The global MIC 90 of these organisms does not
exceed 0.25 mg/L (Hoban et al., 2015); however, that of ESBL-
producing E. coli, Klebsiella species, and A. baumannii is ∼2
mg/L (Hoban et al., 2015). Based on the poor therapeutic
outcome of tigecycline in our study and its low mean peak
concentration in the skin (0.56 ± 0.25 mg/L) reported elsewhere
(Stein et al., 2011), we suggest that a double dose of tigecycline
be used in the treatment of cSSTIs when resistant gram-negative
ecology similar to ours is suspected and when there is no other
alternative.
The management of pneumonia using tigecycline is another
thorny issue. Tigecycline was safe, effective, and non-inferior
to levofloxacin (500 mg/d IV) in hospitalized patients with
CAP, according to two phase III, double-blind trials (Tanaseanu
et al., 2008). However, this dose of levofloxacin is no longer the
standard comparator for non-inferiority. The Infectious Diseases
Society of America (IDSA) guidelines on CAP state that the
recommended dosage for levofloxacin is 750mg daily (Mandell
et al., 2007). In addition, the first investigation to assess the
steady-state intrapulmonary concentrations of tigecycline in a
population of critically ill patients with underlying pulmonary
pathology showed that at 1 h after tigecycline infusion, its
concentration was 0.01 mg/L in the epithelial lining fluid (ELF)
and 1.43 mg/L in the alveolar cells (ACs; Burkhardt et al.,
2009). It is well-known that the antibiotic concentration in ELF
and ACs is an important indicator for treatment success in
lower respiratory tract infections (Mouton et al., 2008). Despite
its low tissue concentration, tigecycline has proven activity in
cases of CAP in which Streptococcus pneumoniae and other
atypical bacteria with low MIC (0.06 mg/L) are suspected
(Hoban et al., 2015). However, when other organisms with higher
MIC (2 mg/L) are suspected, such as non-lactose fermenting
gram-negative rods in patients with pulmonary pathology or
in cases of HAP, the use of tigecycline becomes questionable.
Accordingly, we assume that this issue has played a role in
lowering clinical and microbiological success rates in our cases
of nosocomial pneumonia: 29 and 25%, respectively, for HAP; 26
and 58%, respectively, for VAP. Therefore, we recommend using
tigecycline in CAPwhenMIC 90 of S. pneumoniae is≤0.06mg/L.
If lactose non-fermenters are suspected, double-dose tigecycline
is recommended, but only if there is no alternative.
The use of tigecycline for the treatment of bacteremia is not
advisable because of its low serum concentration. Burkhardt et al.
showed that tigecycline plasma concentrations reach 0.43 ± 0.19
mg/L at 1 h and 0.36± 0.2 mg/L at 4 h after infusion (Burkhardt
et al., 2009). These values are lower than MIC 90 of most gram-
negative bacteria and some of the gram-positive bacteria (Hoban
et al., 2015).
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The use of double-dose tigecycline was based on findings of a
pharmacokinetic study of single and multiple doses administered
to healthy subjects (Muralidharan et al., 2005). Doses ranging
from 12.5 to 300mg were infused over 1 to 4 h. Investigators
concluded that there is a linear correlation between the tested
dose range with the mean maximum concentration (Cmax)
and area under the curve (AUC; Muralidharan et al., 2005).
The highest tolerated dose was 200mg per day (Muralidharan
et al., 2005). However, a recent study showed that high
doses of tigecycline are associated with decreased fibrinogen
level along with prolonged prothrombin time, activated partial
thromboplastin time, and thrombin time (Zhang et al., 2015).
The main driver behind using tigecycline in our institution
is the absence of other suitable alternatives with a relatively safe
toxicological profile and yet good activity against endemic strains
of XDR-AB. In vitro activity of tigecycline was determined by
disc diffusion method in our study. Conflicting evidence lies in
the choice of the testing method, where disc diffusion, Etest,
and VITEK R© 2 may yield false results (Piewngam and Kiratisin,
2014). In addition, no interpretation data are available for
tigecycline susceptibility against A. baumannii from CLSI (2016)
or The European Committee on Antimicrobial Susceptibility
Testing (2016), regardless of the testing method. Nevertheless,
when tigecycline is used, CLSI (2016) and The European
Committee on Antimicrobial Susceptibility Testing (2016)
recommend measuring tigecycline MIC using the recognized
standard of broth microdilution. Accordingly, we recommend
using the broth microdilution method for determining in vitro
activity of tigecycline against endemic strains of Acinetobacter in
corresponding centers.
In our series, tigecycline was used in combination with
other antibiotics based on the growing evidence in the
literature that supports the use of combination therapy against
MDR and XDR organisms. A retrospective cohort study of
236 adult patients with XDR-AB pneumonia showed that a
colistin–tigecycline combination regimen was superior to colistin
monotherapy (Khawcharoenporn et al., 2014). In an attempt to
fight A. baumannii, measuring mutant prevention concentration
(MPC) of an active antibiotic against it can show its propensity
to develop resistance. MPC theory has been proposed as a new
measure for propensity of an antimicrobial to develop resistance
(Zhao and Drlica, 2001). One study assessed the tendency of
A. baumannii to develop resistance through measuring MPC
of tigecycline (Cui et al., 2010). Authors found that tigecycline
MIC is much lower than MPC, which means that attainable
pharmacodynamics with FDA-approved dose will select mutants
for resistance (Cui et al., 2010). Subsequently, tigecycline
monotherapy for XDR-AB is not advisable. Higher doses and
combination therapy with other active drugs such as polymyxins
or rifampicin might lead to promising results (Poulikakos et al.,
2014). We urge that trials examining the optimal treatment
of infections due to MDR and XDR Acinetobacter species
be conducted. A potential study would be testing efficacy of
double-dose tigecycline combined with colistin in cases of XDR
Acinetobacter, in comparison with tigecycline monotherapy.
The limitation of this study lies in its retrospective non-
comparative nature. Because tigecycline was used in combination
with other antibiotics, the individual assessment of its activity
and efficacy was quite difficult. Moreover, it was challenging to
evaluate all patient outcomes, especially in the sick population
suffering from multiple comorbidities, in the absence of a
control group. Data from a single center study like ours might
not be representative of the whole country. Nevertheless, it
could reflect a national perspective on physicians’ prescribing
behaviors, especially that Lebanon is a small country where
the same Infectious Diseases specialists work simultaneously
in different hospitals and use the same prescription strategies.
This study shows a real-life experience in developing countries
where XDR organisms have emerged leaving no room for many
antibiotics to act. Clinicians find themselves facing virulent
pathogens with very limited treatment options, yet with a
nephrotoxic and neurotoxic profile, namely colistin. This reality
highlights the importance of fully engaging pharmacokinetic
and pharmacodynamic principles to optimize antimicrobial
treatment in the face of emerging resistance. Furthermore, each
healthcare facility should properly employ exact microbiological
techniques for testing in vitro susceptibility of its endemic
strains.
CONCLUSION
Based on our results, we found that tigecycline was mostly
used in off-label indications and in patients with high severity
of illness scores (SOFA score ≥7). Those patients showed the
worse outcomes and highest mortality rates. A drug oriented
comprehensive antibiotic stewardship program is needed to
improve patients’ outcomes, curb resistance, and decrease costs.
It should include therapeutic pathways that assign tigecycline use
to each indication according to the type of infecting organism:
starting at the bench, reaching the bedside.
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